selected publications
-
academic article
-
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
Nature Genetics.
50.
2018
Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.
Molecular Oncology.
12.
2018
Contribution of allelic imbalance to colorectal cancer.
Nature Communications.
9.
2018
Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
European Urology Focus.
4.
2018
Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.
Clinical Epigenetics.
10.
2018
Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases.
British Journal of Cancer.
119.
2018
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.
Nature Communications.
9.
2018
Molecular markers increase precision of the European Association of Urology non-muscle invasive bladder cancer progression risk groups.
Clinical Cancer Research.
24.
2018
Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival.
npj Genomic Medicine.
3.
2018
Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study.
BMC Family Practice.
19.
2018
Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
Annals of Oncology.
29.
2018
A genetically inducible porcine model of intestinal cancer.
Molecular Oncology.
11.
2017
An Optimized Shotgun Strategy for the Rapid Generation of Comprehensive Human Proteomes.
Cell Systems.
4.
2017
Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.
Clinical Cancer Research.
23.
2017
Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
International Journal of Molecular Sciences.
18.
2017
Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer.
Scientific Reports.
7.
2017
Direct detection of early-stage cancers using circulating tumor DNA.
Science Translational Medicine.
9.
2017
Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994–2014: A Nationwide Study.
Thyroid.
27.
2017
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
The Journal of Urology.
197.
2017
Founder Effect of the RETC611Y Mutation in Multiple Endocrine Neoplasia 2A in Denmark: A Nationwide Study.
Thyroid.
27.
2017
Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.
Scientific Reports.
7.
2017
Identifying aggressive prostate cancer foci using a DNA methylation classifier.
Genome Biology.
18.
2017
Incidence and prevalence of multiple endocrine neoplasia 2B in Denmark: a nationwide study.
Endocrine Related Cancer.
24.
2017
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
European Urology.
71.
2017
Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer.
Cell Reports.
19.
2017
Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer.
Scientific Reports.
7.
2017
Prognostic Impact of a 12-gene Progression Score in Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
European Urology.
72.
2017
RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Oncotarget.
5.
2017
Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
The Journal of Urology.
197.
2017
epiG: statistical inference and profiling of DNA methylation from whole-genome bisulfite sequencing data.
Genome Biology.
18.
2017
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.
Gut.
65.
2016
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.
Cancer Cell.
30.
2016
Ectodermal dysplasia with immunodeficiency caused by a branch-point mutation in IKBKG/NEMO.
Journal of Allergy and Clinical Immunology.
138.
2016
Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
European Urology.
70.
2016
HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.
Oncotarget.
5.
2016
Large‐scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.
Molecular Oncology.
10.
2016
Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
Oncotarget.
7.
2016
Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma.
Cancer Research.
76.
2016
Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness.
BJU International.
118.
2016
SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism.
Molecular Oncology.
10.
2016
SNHG5 promotes colorectal cancer cell survival by counteracting STAU1-mediated mRNA destabilization.
Nature Communications.
7.
2016
Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma.
Molecular Oncology.
10.
2016
Widespread DNA hypomethylation and differential gene expression in Turner syndrome.
Scientific Reports.
6.
2016
miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells.
Nature Communications.
7.
2016
miRNA profiling of circulating EpCAM+ extracellular vesicles: promising biomarkers of colorectal cancer.
Journal of Extracellular Vesicles.
5.
2016
BS-SNPer: SNP calling in bisulfite-seq data.
Bioinformatics.
31.
2015
Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy.
Scientific Reports.
5.
2015
Functional IRF3 deficiency in a patient with herpes simplex encephalitisIRF3 deficiency and herpes simplex encephalitis.
Journal of Experimental Medicine.
212.
2015
Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients.
Leukemia.
29.
2015
High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer.
Clinical Epigenetics.
7.
2015
Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications.
European Urology.
67.
2015
Mutations in the TLR3 signaling pathway and beyond in adult patients with herpes simplex encephalitis.
Genes & Immunity.
16.
2015
Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case–control study.
BMC Cancer.
15.
2015
Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.
Cancer Epidemiology Biomarkers & Prevention.
24.
2015
SMAP: a streamlined methylation analysis pipeline for bisulfite sequencing.
GigaScience.
4.
2015
A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect.
Nature Communications.
5.
2014
A Dual Program for Translation Regulation in Cellular Proliferation and Differentiation.
Cell.
158.
2014
Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties.
Cancer Research.
74.
2014
Common variant at 16p11.2 conferring risk of psychosis.
Molecular Psychiatry.
19.
2014
Comparative analysis of discrete exosome fractions obtained by differential centrifugation.
Journal of Extracellular Vesicles.
3.
2014
External Validation of a Multiplex Urinary Protein Panel for the Detection of Bladder Cancer in a Multicenter Cohort.
Cancer Epidemiology Biomarkers & Prevention.
23.
2014
Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer.
PLoS ONE.
9.
2014
Genome-wide study of association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci.
Molecular Psychiatry.
19.
2014
High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer.
BMC Cancer.
14.
2014
High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy.
BMC Cancer.
14.
2014
Hypermethylation of the GABRE∼miR-452∼miR-224 Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy.
Clinical Cancer Research.
20.
2014
Identification of expressed and conserved human noncoding RNAs.
RNA.
20.
2014
LIMD2 Is a Small LIM-Only Protein Overexpressed in Metastatic Lesions That Regulates Cell Motility and Tumor Progression by Directly Binding to and Activating the Integrin-Linked Kinase.
Cancer Research.
74.
2014
Mnk2 Alternative Splicing Modulates the p38-MAPK Pathway and Impacts Ras-Induced Transformation.
Cell Reports.
7.
2014
Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer.
Cell Reports.
7.
2014
Next-Generation Sequencing of RNA and DNA Isolated from Paired Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Samples of Human Cancer and Normal Tissue.
PLoS ONE.
9.
2014
Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer.
Annals of Oncology.
25.
2014
Profiling of circulating microRNAs for prostate cancer biomarker discovery.
Drug Delivery and Translational Research.
4.
2014
Prognostic DNA Methylation Markers for Prostate Cancer.
International Journal of Molecular Sciences.
15.
2014
Putative cis-regulatory drivers in colorectal cancer.
Nature.
512.
2014
Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Proteomics.
14.
2014
Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours.
PLoS ONE.
9.
2014
Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome.
European Urology.
65.
2014
-
dataset
-
Distribution of patients over the risk groups for all patients (n = 1892) and BCG treated patients (n = 449)..
public-library-of-science.
2014
Expression of known direct miR-375 targets..
public-library-of-science.
2014
Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer.
public-library-of-science.
2014
Next-Generation Sequencing of RNA and DNA Isolated from Paired Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Samples of Human Cancer and Normal Tissue.
public-library-of-science.
2014
Overview of the different experiments included in this study..
public-library-of-science.
2014
Patient characteristics of 1,892 patients with non-muscle invasive bladder cancer in the participating cohorts.*.
public-library-of-science.
2014
Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours.
public-library-of-science.
2014
Summary of patients and sample characteristics..
public-library-of-science.
2014
The most differentially expressed miRNAs in stage II colorectal adenocarcinomas and their ability to induce phenotypic changes in the high-throughput analysis..
public-library-of-science.
2014
Variants identified in the colon KRAS/BRAF variants detection set..
public-library-of-science.
2014
-
hide from search
-
Description of practice and participant sample at baseline..
public-library-of-science.
2020
Primary and secondary outcomes after 2 years’ follow-up: Adjusted multilevel logistic regression model (OR)..
public-library-of-science.
2020
The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.
public-library-of-science.
2020
Unadjusted primary and secondary outcomes after 2 years’ follow-up..
public-library-of-science.
2020
Changes in gene expression by gene chip analysis – hypoxia compared to normoxia..
public-library-of-science.
2013
Colon cancer cells depleted from KRT23 compared to control cells..
public-library-of-science.
2013
Differentially regulated genes in the right ventricle of pulmonary trunk banded (PTB) rats versus chronic hypoxic rats..
public-library-of-science.
2013
Experimental design..
public-library-of-science.
2013
File S1 - Keratin23 (KRT23) Knockdown Decreases Proliferation and Affects the DNA Damage Response of Colon Cancer Cells.
public-library-of-science.
2013
KRT23 knockdown affects canonical pathways involved in DNA damage control..
public-library-of-science.
2013
Parameters describing the pulmonary and systemic impact of hypoxia..
public-library-of-science.
2013
A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine.
Clinical Cancer Research.
2013
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.
Human Molecular Genetics.
2013
DNA Methylation Signatures for Prediction of Biochemical Recurrence After Radical Prostatectomy of Clinically Localized Prostate Cancer.
Journal of Clinical Oncology.
2013
High expression of microRNA‐625‐3p is associated with poor response to first‐line oxaliplatin based treatment of metastatic colorectal cancer.
Molecular Oncology.
2013
Keratin23 (KRT23) Knockdown Decreases Proliferation and Affects the DNA Damage Response of Colon Cancer Cells.
PLoS ONE.
2013
MiRNA‐362‐3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer.
International Journal of Cancer.
2013
Multicenter Validation of Cyclin D1, MCM7, TRIM29, and UBE2C as Prognostic Protein Markers in Non-Muscle–Invasive Bladder Cancer.
American Journal Of Pathology.
2013
Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer.
British Journal of Cancer.
2013
The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis.
Cell Death & Differentiation.
2013
The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers.
The Journal of Pathology.
2013
Demographic and clinical characteristics of bladder cancer patients and control individuals..
public-library-of-science.
2012
Diagnosis of Bladder Cancer Recurrence Based on Urinary Levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation.
public-library-of-science.
2012
Diagnostic significance of the urinary markers for surveillance of bladder cancer when including a 12-months follow-up period..
public-library-of-science.
2012
Diagnostic significance of the urinary markers for surveillance of bladder cancer..
public-library-of-science.
2012
Diagnostic significance of the urinary markers..
public-library-of-science.
2012
Microsatellite markers selected for this study..
public-library-of-science.
2012
Observed heterozygosity and percentage LOH/AI in tumor samples for each marker..
public-library-of-science.
2012
Results of the microsatellite analysis of pre-TUR urine samples..
public-library-of-science.
2012
Selection of Microsatellite Markers for Bladder Cancer Diagnosis without the Need for Corresponding Blood.
public-library-of-science.
2012
Upper and lower borders set at 95% specificity based on urine samples from healthy individuals..
public-library-of-science.
2012
-
patent
-
A MICRORNA-BASED METHOD FOR ASSESSING THE PROGNOSIS OF A PROSTATE CANCER PATIENT
2019
A MICRORNA-BASED METHOD FOR EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES
2019
MicroRNA-based method for early detection of prostate cancer in urine samples
2019
Microrna-based method for assessing the prognosis of a prostate cancer patient
2019
A MICRORNA-BASED METHOD FOR ASSESSING THE PROGNOSIS OF A PROSTATE CANCER PATIENT
2018
A MICRORNA-BASED METHOD FOR ASSESSING THE PROGNOSIS OF A PROSTATE CANCER PATIENT
2018
Biomarkers for prostate cancer
2018
MICRORNA-BASED METHOD FOR EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES
2018
A MICRORNA-BASED METHOD FOR EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES
2017
A MICRORNA-BASED METHOD FOR ASSESSING THE PROGNOSIS OF A PROSTATE CANCER PATIENT
2016
A MICRORNA-BASED METHOD FOR EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES
2016
BIOMARKERS FOR PROSTATE CANCER
2015
-
preprint